VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC®-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC®-TCE candidate for future clinical development (https://ibn.fm/zBiDU).
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability, and efficacy. The PEI’s feedback provides early guidance on VERAXA’s biological rationale, safety assessments, and non-clinical development plan for its novel therapeutic platform. By obtaining this regulatory guidance, VERAXA believes it can reduce development uncertainty by gaining greater clarity on key scientific and regulatory requirements before advancing toward clinical studies.
The company’s lead BiTAC®-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting. These data demonstrated the platform’s potential in engaging T cells to target and eliminate cancer cells. The BiTAC®-TCE platform is designed to overcome limitations of traditional bispecific T-cell engagers by incorporating optimized binding domains and improved pharmacokinetic properties.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”), and other engineered antibody formats. The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer. The positive feedback from PEI is expected to facilitate discussions with other regulatory agencies and support the company’s overall clinical development plan.
This development is important because it validates VERAXA’s approach to designing its BiTAC®-TCE platform and provides a clearer regulatory pathway. By securing early regulatory alignment, the company can potentially accelerate its timeline to first-in-human trials and reduce the risk of costly late-stage failures. For investors, this milestone reduces some uncertainty around the lead program and highlights VERAXA’s ability to navigate complex regulatory landscapes. The company’s progress also underscores the growing interest in bispecific T-cell engagers as a promising class of cancer immunotherapy.
Forward-looking statements in this article involve risks and uncertainties, including those described in VERAXA’s filings with the SEC. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
